ACRIVON ANNOUNCES LATE-BREAKING ORAL PLENARY PRESENTATION OF EARLY PHASE 1/2 CLINICAL RESULTS IN AP3-PREDICTED TUMORS FOR ITS FIRST-IN-CLASS WEE1/PKMYT1 INHIBITOR ACR-2316 AT THE 38TH EORTC-NCI-AACR SYMPOSIUM

Reuters · 4d ago

Please log in to view news